Key insights
- PacBio's partnership with Lucid Genomics to enhance tertiary analysis of long-read sequencing data is a moderately positive signal. It expands PacBio's ecosystem and improves the usability of its HiFi sequencing technology, potentially driving adoption and revenue. The collaboration focuses on unlocking diagnostic value from previously inaccessible genomic regions.
MENLO PARK, Calif. & BERLIN - PacBio (NASDAQ:PACB) announced Monday that Lucid Genomics GmbH has joined its Compatible partner program as a solution for tertiary analysis of data generated on PacBio long-read sequencing instruments.
Tertiary analysis translates processed genomic data into biological and clinical insights through annotation, interpretation, and reporting of genomic variants. The collaboration enables interoperability between Lucid Genomics’ analysis platform and PacBio’s HiFi sequencing technology.
PacBio’s Compatible partner program recognizes third-party providers whose solutions work with PacBio instruments and data formats. Lucid Genomics’ platform supports alignment, phasing, variant annotation, methylation analysis, and visualization tasks designed for PacBio HiFi reads.
"Long-read sequencing is unlocking parts of the genome that were simply invisible before: non-coding regions, methylation patterns, structural variants in the dark genome," said Dr. Uira Souto Melo, Founder and CEO of Lucid Genomics. "Lucid was built from the ground up as a long-read native company to extract exactly this kind of diagnostic value."
Dave Miller, Vice President of Global Marketing at PacBio, said the company aims to build an ecosystem of compatible solutions enabling customers to realize the value of HiFi sequencing. "Lucid Genomics brings a powerful, long-read-native approach to tertiary analysis," Miller stated.
The companies may collaborate on joint customer engagements, technical resources, and co-marketing initiatives. Lucid Genomics’ cloud-native platform is designed to provide laboratories using PacBio systems with production-ready tertiary analysis workflows.
The information is based on a press release statement from the companies.
In other recent news, Pacific Biosciences announced a joint workflow with Covaris for HiFi sequencing of formalin-fixed, paraffin-embedded tissue samples. The protocol combines Covaris truXTRAC FFPE extraction technology with PacBio’s Kinnex library preparation and sequencing on the Revio system. Canaccord Genuity reiterated a Buy rating on Pacific Biosciences, highlighting the planned commercial launch of SPRQ-Nx chemistry and reusable SMRT cells, which are expected to enhance data yield and reduce costs by the second half of 2026. Meanwhile, Barclays downgraded the stock to Underweight, citing a lack of immediate upside drivers from the SPRQ NX technology.
Additionally, Pacific Biosciences announced the resignation of Michele Farmer as Chief Accounting Officer, effective March 21, noting that her departure is not related to any operational disagreements. The company also appointed Christopher Gibson, co-founder of Recursion, to its Board of Directors. In legal matters, Pacific Biosciences reached a settlement in ongoing litigation, as disclosed in a recent SEC filing. These developments reflect the company’s ongoing strategic adjustments and technological advancements.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.